Get informed when a big investor buys or sells
+ Follow4.10%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
StemCell Institute (7096.T) currently reports a ROE of 4.1%. That is below the Healthcare sector average of 13.1%. Use the charts on this page to explore StemCell Institute's ROE history and peer comparisons.
StemCell Institute's ROE of 4.1% is lower than the Healthcare sector average of 13.1%. That is roughly 68.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but StemCell Institute's current 4.1% should be judged against Healthcare norms (sector average: 13.1%) and against 7096.T's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 4.1%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.1%. From there, open related valuation or income-statement pages for StemCell Institute, and consider following 7096.T for alerts when major investors trade the stock.
StemCell Institute is classified in the Healthcare sector. On ROE, it currently shows 4.1% versus a sector average near 13.1%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing 7096.T with unrelated industries.